期刊文献+

原发性肝细胞癌锰福地匹三钠增强MRI强化指数与其分化程度的相关性探讨 被引量:3

Primary hepatocellular carcinoma: investigation on the correlation between enhancement index on MnDPDP enhanced MRI and tumor differentiation
原文传递
导出
摘要 目的 探讨原发性肝细胞癌 (HCC)的锰福地匹三钠 (MnDPDP)增强MRI强化指数与其分化程度的相关性。方法 将 4 3个由MRI检出并经手术切除治疗的HCC病灶强化指数 ,与其病理分化程度分级进行对照。于轴位正中层面图像上将 4 3个HCC病灶分为均匀强化和不均匀强化 ;将后者分成高、等、低 3个区域 ,并分别计 3、2、1分 ;按不同信号强度区所占该层面的百分比计算不同区域的分值 ,将不同区域的分值相加即得“病灶强化指数” ,最后将病灶强化指数与其病理分级相对照。病理检查取材部位与不同强度信号区相对应 ,并包括瘤 肝交界处。结果 对 4 3个HCC的 113处进行了Edmondson和Steiner分级 :Ⅰ级 13处 ,Ⅰ~Ⅱ级 7处 ,Ⅱ级 5 0处 ,Ⅱ~Ⅲ级 2 2处 ,Ⅲ级 19处 ,Ⅲ~Ⅳ级 1处 ,Ⅳ级 1处。高信号、等信号和低信号分别为 81、17和 15处。增强后HCC高、等、低信号区与其分化程度之间具有显著相关性 (χ2 =2 6 .75 ,P <0 .0 0 5 )。病灶强化指数与其分化程度之间具有显著相关性 (χ2 =7.94 ,P <0 .0 0 5 )。结论 HCCMnDPDP增强MRI强化指数与其分化程度具有显著相关性。 Objective To explore the correlation between the enhancement index of HCC on MnDPDP enhanced MRI and the tumor differentiation. Methods The enhancement indice of 43 HCCs in 34 cases detected on MRI with MnDPDP confirmed surgico-pathologically were analyzed and compared with the HCC differentiation. The 24-hour delayed T 1W SE images enhanced with MnDPDP were employed in this study. The enhancement findings of the lesion foci at their midaxial sections in 43 HCCs were blindly divided into two groups: homogeneity and heterogeneity by 3 experienced radiologists,and for the latter,the regions with different signal intensities (low,iso- or high) were scored 1 to 3 credits. Then,all the lesions including the homogeneous ones were scored and the credits were weighted proportionally by the size of areas in which the different signal intensity dominated. At last,the scores for different areas were summed up to obtain 'Enhancement Index' for the HCC focus respectively. And eventually,the enhancement index for HCC was compared with HCC pathologic grading. The sites for specimen collection were corresponding to the regions with different signal intensities,and the conjunction area between the tumor and liver was also examined pathologically. Results The overall sites for pathologic examination were 125 for the 43 HCCs. The sites of HCCs dominated by fatty changes (2),hyaline-cells (3) and necroses (7) were rejected. Edmondson and Steiner grading was performed for the rest 113 sites of HCC specimens as follows: Ⅰ(13),Ⅰ-Ⅱ(7),Ⅱ(50),Ⅱ-Ⅲ(22),Ⅲ(19),Ⅲ-Ⅳ(1),and Ⅳ(1). On MnDPDP enhanced MR images,the regions of HCCs in high,isointense,and low signal intensity were 81,17,and 15,respectively. There was a significant correlation between the signal intensity on MnDPDP enhanced MRI and the tumor differentiation of HCC on region-by-region basis (χ 2=26.75,P<0.005). And the HCC enhancement index with MnDPDP was significantly correlated with the tumor differentiation (χ 2=7.94,P<0.005). Conclusion The enhancement index of HCC on MnDPDP enhanced MRI was well correlated with the tumor differentiation.
出处 《中华放射学杂志》 CAS CSCD 北大核心 2004年第3期282-286,共5页 Chinese Journal of Radiology
关键词 原发性肝细胞癌 细胞分化 磁共振成像 锰化合物 Carcinoma,hepatocellular Cell differentiation Magnetic resonance imaging Manganese compounds
  • 相关文献

参考文献3

二级参考文献10

  • 1Wang C,Acta Radiologica,1998年,40卷,supplement期,7~31页
  • 2Liou J,Magn Reson Imaging,1994年,12卷,71~79页
  • 3Wang C, Gordon PB, Hustvedt SO, et al. MR imaging properties and phar-macokinetics of MnDPDP in healthy volunteers. Acta Radiologica, 1997,38:665
  • 4Wang C. Mangafodipir trisodium (MnDPDP)-enhanced magnetic resonanceimaging of the liver and pancreas. Acta Radiologica, 1998, 39:7
  • 5Rummeuy EJ, Torres CG, Kurdziel JC, et al. MnDPDP for MR imaging of the liver: results of independent image evaluation of the European phase Ⅲstudies. Acta Radiologica, 1997, 38:638
  • 6Jung G, Heindel W, Krahe T, et al. Influence of the hepatobiliary contrastagent mangafodipir trisodium (MnDPDP) on the imaging properties of the abdominal organ. Magn Reson Imaging, 1998, 16(8):925
  • 7Toft KG, Kindberg GM and Skotland T, et al. Mangafodipir trisodium injec-tion, a new contrast medium for magnetic rsonance imaging. In vitro metaboliem and protien binding studies of the active component MnDPDP in human blood. J Pharm Biomed Anal, 1997,15:983
  • 8Toft KG, Hustvedt SO, Grant D, et al. Metabolism of mangafodipir trisodium (MnDPDP), a new contrast medium for magnetic resonance imaging, in beagle dogs. Eur J Drug Mtab Pharmacokinet, 1997, 22:65
  • 9Hanhn PF, and Saini S. Liver-specific MR imaging contrast agents. Radol Clini Nor Am, 1998, 36:287
  • 10Murakami T, Baron RL, Peterson MS, et al. Hepatocellular carcinoma: MR imaging with m angafodipir trisodium (MnDPDP). Radiology, 1996, 2000:69

共引文献7

同被引文献32

  • 1赵卫东,管生,李卉,奥红,陈中伟,彭卫军,毛健.二乙基亚硝胺诱导大鼠肝细胞癌系列病理改变及其磁共振成像[J].山西医药杂志,2005,34(3):182-185. 被引量:2
  • 2邱立艳,汪建华,陈波,石国儿.35例不同病理亚型的肾癌螺旋CT分析[J].医学影像学杂志,2010,20(12):1843-1846. 被引量:7
  • 3Rock EP,Goodman V,Jiang JX,et al.Food and Drug Administration drug approval summary:Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.Oncologist,2007,12(1):107-113.
  • 4Abel EJ,Culp SH,Tannir NM,et al.Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma.Eur Urol,2011,59(1):10-15.
  • 5Motzer RJ,Hutson TE,Tomczak P,et al.Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.N Engl J Med,2007,356(1):115-124.
  • 6Choi H,Charnsangavej C,Faria SC,et al.Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate:proposal of new computed tomography response criteria.J Clin Oncol,2007,25(13):1753-1759.
  • 7Benjamin RS,Choi H,Macapinlac HA,et al.We should desist using RECIST,at least in GIST.J Clin Oncol,2007,25(13):1760-1764.
  • 8Therasse P,Arbuck SG,Eisenhauer EA,et al.New guidelines to evaluate the response to treatment in solid tumors.European Organization for Research and Treatment of Cancer,National Cancer Institute of the United States,National Cancer Institute of Canada.J Natl Cancer Inst,2000,92(3):205-216.
  • 9van der Veldt AA,Meijerink MR,van den Eertwegh AJ,et al.Sunitinib for treatment of advanced renal cell cancer:primary tumor response.Clin Cancer Res,2008,14(8):2431-2436.
  • 10Motzer RJ,Michaelson MD,Redman BG,et al.Activity of SU11248,a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor,in patients with metastatic renal cell carcinoma.J Clin Oncol,2006,24(1):16-24.

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部